UCB’s bimekizumab tops J&J’s Stelara in psoriasis studyThe first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy Share XUCB’s bimekizumab tops J&J’s Stelara in psoriasis studyhttps://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/